枭雄要成就霸业，需要的不只是一招鲜，而是长期源源不断的竞争力。 陕西女首富范代娣和前山东女首富赵燕，如果不做医美，不关注护肤成分，你可能对这两个名字并不熟 悉。但在如今的中国商业版图上，这两位女性，分别掌控着两家市值几百亿的上市公司——巨子生物和 华熙生物。 表面上看，她们一个在西安，一个在山东；一个做蛋白，一个做多糖；一个出身严谨的大学实验室，一 个来自野蛮生长的地产江湖。她们本该井水不犯河水。 但现实是，这两家公司正在进行一场旷日持久的、甚至可以说是「你死我活」的商战。 但命运和机遇有时候就是不讲道理。 这一年，在北大EMBA的课堂上，她结识了山东省生物药物研究院的副院长郭学平。他跟赵燕说了一句 至今被奉为行业金句的话：「一个玻尿酸分子，能锁住1000个水分子。」 故事的起点，要回到2000年。 这是一个神奇的年份，两人的命运在这一年同时被改写。 当时的赵燕，还是一个在海南淘金成功、在北京开发楼盘的地产大鳄。后来更是在北京开发了中环世贸 中心，承建了奥运会场馆五棵松体育馆，也就是现在的五棵松华熙Live。 按理来说，她的头衔，应该是地产女王，而不是现在的「玻尿酸女王」。 01 她没有亲自去搞研发，而是用资 ...

Summary of Key Points from the Conference Call Industry Overview - The Chinese medical aesthetics market has a significantly lower penetration rate compared to developed countries, with an expected penetration rate of approximately 3.2% by 2025, compared to South Korea's 16.1%, indicating substantial growth potential over the next decade, potentially reaching a market size of 700 to 800 billion or even over 1 trillion yuan [1][4] - The market is currently facing challenges due to consumer fatigue and accelerated regulatory approvals, leading to increased competition and price reductions for products like homologous injections [1][5] Core Insights and Arguments - Medical aesthetics institutions are struggling with high sales expense ratios, often between 30% and 40%, which erodes profits. New business models like the "Xiaoyang model" and "dual beauty integration model" are seen as effective ways to reduce sales costs and improve profitability [2][3] - PDIN (salmon needle) is gaining attention as a new medical aesthetic material due to its high similarity to human DNA, good biocompatibility, and regenerative properties, potentially becoming a new profit growth point for medical aesthetic institutions [1][10] - The leading brand in the Korean PDN market, Rejuran, is expected to generate approximately 870 million yuan in global revenue in 2024, with projections of reaching 1.5 billion yuan in 2025, supported by a planned 25% compound annual growth rate over the next five years [1][17] Investment Opportunities - Investment opportunities in the medical aesthetics industry can be categorized into upstream (new materials) and downstream (medical aesthetic institutions). Upstream new materials are currently a key investment direction, while downstream institutions that can effectively lower sales costs and improve profitability are also valuable [2][6] - Companies like Lepu Medical are actively developing PDI and ECM medical aesthetic products, with PDI products expected to be approved in the first half of 2026, potentially serving as new growth engines for the company [2][23] Competitive Landscape - The competitive landscape for medical aesthetic materials has changed significantly, with new products being approved at a rapid pace, increasing competition and driving down prices for traditional materials like collagen [7][9] - The overall growth rate of the Chinese medical aesthetics industry has slowed to about 10% in recent years, down from over 30% pre-pandemic, with a decline in average transaction prices impacting profit margins [8] Future Outlook - Long-term growth potential remains strong for the Chinese medical aesthetics industry, driven by low current penetration rates and the anticipated normalization of domestic consumption [6] - The demand for PDI materials is expected to increase, with several companies, including Lepu Medical, actively pursuing development in this area, indicating a shift towards new profit sources as traditional materials face declining margins [23] Company-Specific Insights - Lepu Medical's current valuation is considered undervalued at around 30 billion yuan, with a potential market value of at least 40 billion yuan based on its serious medical business, PDIN, and innovative drug potential [2][26] - Rejuran's market share in the Korean PDN market is estimated to be between 70% and 80%, with significant revenue contributions from both domestic and international markets [17][19] Additional Considerations - The approval status of Rejuran in various countries, including Singapore, Thailand, and Australia, is progressing, with pending applications in China and the U.S. that could significantly enhance its global market presence [21] - The ECM component market is also showing potential, with several companies in China working on related products, indicating a growing interest in this area [24][25]

北京华熙荣熙：合成生物学业务的核心创新引擎 作为华熙生物在合成生物学领域的核心布局，北京华熙荣熙生物技术研究有限公司是本次重点实验室建 设的核心技术支撑力量。自成立以来，华熙荣熙始终聚焦高价值生物活性物的合成生物研发，构建了五 大核心技术平台——高通量自动化筛选平台、酶改造与进化平台、AI数据化平台、发酵优化平台及微 生物育种平台，形成了从基因编辑、底盘细胞构建到规模化发酵的全链条研发能力。 过往几年，华熙荣熙先后获评国家高新技术企业、中关村高新技术企业、北京市专精特新中小企业等多 项资质，设立北京市博士后科研工作站园区分站，成为合成生物学领域的创新标杆。在本次重点实验室 建设中，华熙荣熙将牵头负责糖基转移酶、糖苷水解酶等关键酶的挖掘与改造，建立糖生物学研发平 台，开发标准化酶库，底盘微生物细胞工厂、多酶偶联的催化体系等，为糖类精准合成提供核心技术支 撑。 糖生物学：华熙生物的基础战略与核心护城河 近日，北京市科学技术委员会、中关村科技园区管理委员会正式公布2025年北京市重点实验室认定名 单，北京华熙荣熙生物技术研究有限公司（华熙生物合成生物学研发核心板块）与北京大学联合共建 的"糖类智造及功能应用北京市重 ...

海南航空客机 从美兰国际机场起飞 海口新海港和南港"二线 口岸"（货运）集中查验场。 记者 刘逸鹏 摄 ◎林铭溱 记者 刘逸鹏 海南自由贸易港，迎来了全岛封关运作的历史性时刻。 因改革开放而生，因改革开放而兴。海南正以"管得住"的底气和"放得开"的魄力，将地理意义上的"天 涯"转变为改革开放的新高地。 近日，上海证券报记者深入海南一线，感触这座热带岛屿在改革大潮中律动的强劲脉搏，聆听这片开放 新高地正在加速"蝶变"的时代声音。 产业升级 加速"蝶变" 昼夜更迭，三亚崖州湾科技城被两种"光"依次照亮——白天是北纬18度热烈的阳光，夜晚是实验室里奋 斗的灯光。 时至今日，华大集团海南区域总经理、三亚华大生命科学研究院院长岳震仍清楚记得2021年初到崖州湾 畔的情景。 "一开始，到处是工地，生活条件并不便利。我们要打造新的平台和团队，一切都需要从零起步。"岳震 感叹，时光飞逝，变化每一刻都在发生。四年来，团队人员从最初的4人发展至超过100人，与22所高校 建立实习和联合培养人才模式。现在，华大集团在崖州湾科技城内已有四处实验室，研究领域覆盖生物 育种与海洋生物制造，年投入已经超过1亿元。 海口新海客运综合枢纽 实 ...

作者： 林京 来源： Tech星球 医美巨头华熙生物，依旧在经历阵痛期。 以下文章来源于Tech星球 ，作者林京 ------------------------------- Tech星球 . Tech星球，聚焦互联网前沿科技和新商业。 随着玻尿酸市场红利消退，华熙生物的业绩还在不断承压。 今年前三季度，华熙生物营业收入同比 减少18.36%至31.63亿元，归母净利润较上年同期下滑30.29%至2.52亿元。 12月5日，华熙生物股价更是以45.57元收盘， 跌破47.79元的发行价，总市值仅剩220亿， 相较 昔日最高峰1400亿市值，已经蒸发千亿。 此外，据凤凰网科技等报道，华熙生物发布了一封"同舟共济、共克时艰"的全员邮件，称受市场环 境波动影响，公司经营业绩面临较大压力。为确保长期稳健发展，公司需对现有福利政策进行合规 性优化调整。 其中，白2025年12月起，华熙生物及各分子公司的住房公积金缴存比例统一调整为5%。 自2025 年12月起，原设定的节日礼金将暂停发放。后续公司将通过员工关怀活动、弹性福利平台等方式， 持续关注大家的工作与生活需求。 截至发稿，华熙生物对此邮件内容暂无公开回应。 尽 ...

Core Viewpoint - The stock price of Hyaluronic Acid leader, Huaxi Biological (688363.SH), has fallen below its issue price, reflecting concerns over its performance and market conditions [1][3]. Financial Performance - For the first three quarters of 2025, Huaxi Biological reported revenue of 3.163 billion yuan, a year-on-year decline of 18.36% [3]. - The net profit attributable to shareholders was 252 million yuan, down 30.29% year-on-year, continuing the downward trend from 2024 [3]. - In Q3 2025, despite a 55.63% increase in net profit to 32 million yuan, revenue of 900 million yuan still represented a 15.16% year-on-year decline, indicating a situation of "profit increase without revenue increase" [3]. Market Capitalization and Stock Performance - The company's market capitalization has decreased to approximately 22 billion yuan, down over 118 billion yuan from its peak value of over 140 billion yuan [3]. - The stock has seen a cumulative decline of 10.53% this year, with a historical low of 42.42 yuan per share [3]. Shareholder Actions - The second-largest shareholder, Guoshou Chengda, plans to reduce its holdings by up to 9.6336 million shares, representing no more than 2% of the total share capital, with an estimated market value of around 500 million yuan based on the closing price of 52.05 yuan per share on November 4 [4]. - This marks the second reduction by Guoshou Chengda in the past year, having previously sold 549.68 million shares [4]. Index Exclusions - Huaxi Biological has been removed from two major indices: the STAR 50 Index and the FTSE China A400 Index, which will take effect on December 12 and December 19, respectively [4]. Industry Competition - The competitive landscape is shifting, with a debate over the relevance of hyaluronic acid versus collagen in skincare. Market trends suggest that collagen-based skincare may surpass hyaluronic acid, with a projected compound annual growth rate of 52.6% [4]. Strategic Initiatives - In response to these pressures, Huaxi Biological has initiated organizational restructuring and is focusing on strategic investments in new biotechnologies, such as PDRN and ergothioneine, which are expected to contribute to revenue growth in 2026 [5].

Core Viewpoint - The report from China Galaxy Securities highlights optimism for investment opportunities in the pharmaceutical industry by 2026, suggesting that after recent fluctuations, valuations have returned to relatively low levels, with a potential for a resurgence in growth [1] Investment Outlook - The pharmaceutical sector is expected to see significant differentiation in 2025, with various factors driving rapid growth in the innovative drug segment, particularly in the Hong Kong market [2] - China's innovative drug development is gaining a competitive edge globally due to cost advantages and efficient conversion capabilities, transitioning from a "technology follower" to a "leading participant" in the global pharmaceutical innovation landscape [2] Policy Outlook for 2026 - The 14th Five-Year Plan marks a year of deepening collaboration in the healthcare system, with policies expected to enhance the efficiency of medical insurance funds and support for innovative drugs and devices [3] - The focus will be on optimizing procurement rules to balance quality and innovation, driving domestic alternatives, and improving public health capabilities [3] Sector-Specific Investment Insights - **Innovative Drugs**: Anticipated breakthroughs in domestic innovative drugs, with several promising candidates entering late-stage clinical trials [4] - **Life Sciences and CXO Sector**: A structural recovery is expected as global financing conditions improve and domestic innovation ecosystems stabilize [4] - **Medical Devices**: Growth opportunities in the domestic medical device sector are anticipated, particularly in aging-related markets and overseas exports [4] - **Traditional Chinese Medicine and Biologics**: Market dynamics may shift due to clinical re-evaluations, with potential changes in profit margins for traditional Chinese medicine [4] Healthcare Services - The aging population presents a reliable opportunity in the healthcare services sector, emphasizing the importance of maintaining a strong position in this area [5] Aesthetic Medicine - Upgrades in ingredient formulations and the rise of domestic brands in aesthetic medicine are noteworthy, with a focus on specific segments like collagen and botulinum toxin [6] Pharmaceutical Commerce - Attention is drawn to accounts receivable turnover, with a positive outlook on new business models in Contract Sales Organizations (CSO) [7] Medical AI - The acceleration of artificial intelligence in healthcare is expected to significantly enhance clinical service capabilities and efficiency, particularly in medical diagnostics [7]

Core Insights - The 2025 Double Eleven shopping festival achieved a record online retail sales of nearly 2.4 trillion yuan, marking a year-on-year growth of over 10% [1] - The beauty category, particularly high-end skincare, showed significant growth driven by trends towards premiumization and rational consumer choices regarding ingredients [1][2] Sales Performance - During Double Eleven, nearly 2,000 beauty, apparel, and sports brands on JD saw their sales double year-on-year, with around 500 subcategories also experiencing similar growth [1] - The growth rates for key beauty subcategories on major e-commerce platforms were led by JD's facial skincare at 12.1%, followed by Douyin at 10.5%, and Taobao and Pinduoduo at 7.3% and 6.2% respectively [1] Consumer Behavior - Over 90% of consumers are now more rational and professional in their selection of beauty products, with 59% choosing products based on their skin type [2] - Familiarity with classic ingredients such as hyaluronic acid, collagen, and niacinamide is high, with recognition rates of 66.8%, 61.9%, and 57.3% respectively [2] Competitive Landscape - In the high-end skincare segment, 93.6% of consumers prefer purchasing from JD due to its reputation for genuine products, delivery speed, after-sales quality, and overall service, surpassing Taobao/Tmall at 43% [5] - JD has become the largest online sales channel for numerous international beauty brands, including Lancôme, La Mer, Helena Rubinstein, Estée Lauder, YSL, Armani, SK-II, Dior, and Givenchy [5] Market Trends - The beauty industry is becoming increasingly competitive, with consumers demanding more rational and precise skincare solutions [5] - Platforms must strengthen their authenticity measures, optimize service chains, and continuously expand their product offerings to meet the evolving beauty consumption demands of consumers [5]

Core Insights - The collagen market is experiencing a downturn, with major brands like Kefu Mei and Juzhi Biotech showing a decline in growth and sales performance [1][5][6] - The market is undergoing a transformation, moving from a focus on consumer beauty products to medical applications, as companies adapt to changing consumer demands and competitive pressures [9][12][13] Market Performance - Kefu Mei's GMV on Douyin dropped to 0.5-0.75 billion yuan from over 1 billion yuan year-on-year [5] - Juzhi Biotech's stock price has fallen by 55.18% since reaching a peak of 85.14 HKD on May 20, 2023 [6][7] - The overall sales performance of collagen brands during the 2025 Double Eleven shopping festival was disappointing compared to previous years [5] Strategic Shifts - Juzhi Biotech is expanding into the B2B market by obtaining medical device registration for a collagen-based product, indicating a strategic shift towards medical applications [7][12] - Companies are increasingly focusing on technological advancements and clinical applications rather than just marketing and branding [10][13] Industry Trends - The collagen industry is moving away from purely cosmetic applications towards medical uses, with a focus on proving efficacy through clinical trials and regulatory approvals [9][12][13] - The competitive landscape is evolving, with companies needing to demonstrate the scientific validity of their products to gain market share [12][13] Innovation and Development - Huaxi Biotech is actively pursuing new patents related to collagen, indicating ongoing investment in research and development [10][11] - Companies like Furuida and Mianmei are also advancing in the medical device space, with new certifications and product developments aimed at surgical applications [12][13]

Group 1 - The company, Dongbao Biological (300239), primarily engages in the research, production, and sales of gelatin, collagen, hollow capsules, and their derivatives [1] - The company has clarified that it does not involve itself in the rare earth sector [1]